Therapnea SIGNED
Therapnea: Novel Therapy to treat Obstructive Sleep Apnea based on Thomas Oro-Pharyngeal Stent
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Therapnea project word cloud
Explore the words cloud of the Therapnea project. It provides you a very rough idea of what is the project "Therapnea" about.
Project "Therapnea" data sheet
The following table provides information about the project.
| Coordinator |
THOMAS MEDICAL LTD
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Project website | http://www.therapnea.net |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.4. (Active ageing and self-management of health) 2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.1.6. (Health care provision and integrated care) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-09-01 to 2018-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THOMAS MEDICAL LTD | IL (TEL AVIV) | coordinator | 50˙000.00 |
Map
Project objective
Obstructive sleep apnea is the most common organic sleep disorder in which the respiratory path becomes occluded during sleep, usually due to collapse of the upper airways, causing the patient to stop breathing, with severe co-morbidity issues. Although there are several known therapies for apnea (behavioural, devices or surgery), none is as successful and effective as using compressed air respiratory support to keep the airways open during sleep, making CPAP (Continuous Positive Airway Pressure) the most common treatment of choice. Unfortunately, it still has many limitations regarding patient’s compliance, and it is ONLY SUCCESSFUL FOR 50% OF PATIENTS. According to the World Health Organisation (WHO), over 100 Million people worldwide suffer sleep apnea and its related morbidity and mortality risks. Tens of millions are unable to adhere or abandon current therapies, with CPAP as the first line of treatment. Low CPAP compliance, mainly due to major discomfort, is recognized as the major issue, and many companies are investigating ways to improve it. Sleep apnea devices market size is worth USD 8.8 billion by 2023, with 7.7% CAGR from 2016 to 2023. We at Thomas Medical Ltd. have been working on the development of a disruptive solution to respond to the unmet needs of patients that can’t adhere current therapies. The invention is an upper airway stenting device intended for the treatment of adult obstructive sleep apnea. The device, Therapnea™, operates by providing mechanical support to the walls of the pharynx and the back of the tongue, thereby preventing their collapse and eliminating partial or complete airway obstruction during sleep. We aim to provide effective therapy to the tens of millions of sleep apnea patients who can’t be helped with current CPAP devices or surgeries, and thus become the first line of treatment in the long term.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPNEA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THERAPNEA" are provided by the European Opendata Portal: CORDIS opendata.